At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular subgroups of triple-negative breast cancer that may have potential to be exploited for clinical trial development of new therapies, including enzalutamide, an androgen receptor signalling inhibitor; and pembrolizumab, an anti-PD-1 monoclonal antibody.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement